АДЪЮВАНТНОЕ ЛЕЧЕНИЕ РАКА ЖЕЛУДКА
Аннотация
В статье проанализированы результаты рандомизированных многоцентровых исследований, посвященных выяснению роли адъювантной и неоадъювантной химиотерапии, таргетной терапии, адъювантного химиолучевого лечения в улучшении результатов хирургического лечения рака желудка.
Ключевые слова
Об авторах
Д. Т. Арыбжанов
Южно-Казахстанский областной онкологический диспансер
Казахстан
Казахстан
Арыбжанов Дауранбек Турсункулович - заведующий отделением химиотерапии и эндоваскулярной онкологии ГККП Южно-Казахстанского областного онкологического диспансера, кандидат медицинских наук.
160021, Шымкент, ул. А. Байтурсынова, б/н, тел. 8 (7252) 22-19-54, e-mail: davran_a@mail.ru
И. Р. Рахматуллина
Башкирский государственный медицинский университет
Россия
Россия
Рахматуллина Ирина Робинзоновна - декан лечебного факультета БГМУ, доктор медицинских наук, профессор кафедры онкологии с курсами онкологии и патологической анатомии БГМУ
Список литературы
1. Bang Y., Kim Y.W., Yang H. et al. Adjuvant capecitabine and oxaliplatin for gastric cancer: results of the phase III CLASSIC trial. 2011 ASCO Annual Meeting // J Clin Oncol. – 2011. – Vol. 29.
2. Bang Y.J., Kim Y.W., Yang H.K. et al Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial // Lancet. – 2012.
3. Bang Y.J., Van Cutsem E., Feyereislova A. et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial // Lancet. – 2010. – Vol. 376. – P. 687-697.
4. Chen S., Feng X., Li Y. et al. Efficacy and safety of XELOX and FOLFOX6 adjuvant chemotherapy following radical total gastrectomy // Oncol Lett. – 2012. – Vol. 3. – №4. – P. 781-786.
5. Chin J. A phase II study of preoperative chemotherapy with modified FOLFOX6 followed by surgery and postoperative chemoradiation in patients with localized gastric adenocarcinoma / Chen S.S., Yang X.C., Chi F., Yu W.Z., Wang Z.B., Ning F.L., Yu Z.S., Hao Y.Z., Li M.L., Wang F., Geng D.Z., Liu L.H., Dong X.J., Peng X.Z., Ji C.X. // Cancer Res. – 2013. – Vol. 25. – №4. – P. 479-481.
6. Chung M.J., Kim H., Jung Y.S., Shin S.K., Hyung W.J., Noh S.H., Seong J., Lee Y.C., Song S.Y. A pilot study for preoperative concurrent chemoradiotherapy with S-1 and cisplatin for locally advanced gastric cancer // Hepatogastroenterology. – 2013. – Vol. 60. – №122. – P. 382-386.
7. Cirera L., Balil A., Batiste-Alentorn E. et al. Randomized clinical trial of adjuvant mitomycin plus tegafur in patients with resected stage III gastric cancer // J Clin Oncol. – 1999. – Vol. 17. – №12. – P. 3810-3815.
8. Coburn N., Seevaratnam R., Paszat L. et al. Optimal Management of Gastric Cancer: Results From an International RAND/UCLA Expert Panel // Ann Surg. – 2013.
9. Coombes R.C., Schein P.S., Chilvers C.E. et al. A randomized trial comparing adjuvant fluorouracil, doxorubicin, and mitomycin with no treatment in operable gastric cancer. International Collaborative Cancer Group // J Clin Oncol. – 1990. – Vol. 8. – №8. – P. 1362-1369.
10. Cunningham D., Allum W.H., Stenning S.P. et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer // N Engl J Med. – 2006. – Vol. 355. – №1. – P. 11-20.
11. Curr Treat Options Oncol. Treatment options for surgically resectable gastric cancer / Rajdev L. // – 2010. – Vol. 11. – №1-2. – P. 14-23.
12. Dikken J.L., van Sandick J.W., Maurits Swellengrebel H.A., et al. Neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy for patients with resectable gastric cancer (CRITICS) // BMC Cancer. – 2011. – Vol. 2. – №11. – P. 329.
13. Dikken J.L., Jansen E.P., Cats A. et al. Impact of the extent of surgery and postoperative chemoradiotherapy on recurrence patterns in gastric cancer // J Clin Oncol. – 2010. – Vol. 28. – №14. – P. 2430-2436.
14. D'Ugo D., Rausei S., Biondi A., Persiani R. Preoperative treatment and surgery in gastric cancer: friends or foes? // Lancet Oncol. – 2009. – Vol. 10. – №2. – P. 191-195.
15. Earle C.C., Maroun J.A. Adjuvant chemotherapy after curative resection for gastric cancer in non-Asian patients: revisiting a meta-analysis of randomised trials // Eur J Cancer. – 1999. – Vol. 35. – №7. – P. 1059-1064.
16. Gallo A., Cha C. Updates on esophageal and gastric cancers // World J Gastroenterol. – 2006. – Vol. 12. – №957. – P. 3237-3242.
17. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group. Paoletti X., Oba K., Burzykowski T., Michiels S., Ohashi Y., Pignon J.P., et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis // JAMA. – 2010. – Vol. 303. – P. 1729-1737.
18. GLOBOCAN 2008. Cancer Incidence and Mortality Worldwide // IARC CancerBase No. 10 [Internet]. Lyon, France International Agency for Research on Cancer. – 2010.
19. Gunderson L.L. Gastric cancer-patterns of relapse after surgical resection // Semin Radiat Oncol. – 2002. – Vol. 12. – P. 150-161.
20. Hallissey M.T., Dunn J.A., Ward L.C., Allum W.H. The second British Stomach Cancer Group trial of adjuvant radiotherapy or chemotherapy in resectable gastric cancer: five-year follow-up // Lancet. – 1994. – Vol. 343. – №8909. – P. 1309-1312.
21. Han D.S., Suh Y.S., Kong S.H. et al. Outcomes of surgery aiming at curative resection in good responder to induction chemotherapy for gastric cancer with distant metastases // J Surg Oncol. – 2013. – Vol. 107. – №5. – P. 511-516.
22. Hermans J., Bonenkamp J.J., Boon M.C. et al. Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials // J Clin Oncol. – 1993. – Vol. 11. – №8. – P. 1441-1447.
23. Hudis C.A. Trastuzumab--mechanism of action and use in clinical practice // N Engl J Med. – 2007. – Vol. 357. – P. 39–51.
24. Inoue M., Tsugane S. Epidemiology of gastric cancer in Japan // Postgrad Med J. – 2005. – Vol. 81. – №957. – P. 419-424
25. Iwasaki Y., Sasako M., Yamamoto S. et al. Gastric Cancer Surgical Study Group of Japan Clinical Oncology Group. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210) // J Surg Oncol. – 2013. – Vol. 107. – №7. – P. 741-745.
26. Janunger K.G., Hafstrom L., Glimelius B. Chemotherapy in gastric cancer: a review and updated meta-analysis // Eur J Surg. – 2002. – Vol. 168. – №11. – P. 597-608.
27. Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (ver. 3) // Gastric Cancer. – 2011. – Vol. 14. – P. 113-123.
28. Kerkar S.P., Kemp C.D., Duffy A. et al. The GYMSSA trial: a prospective randomized trial comparing gastrectomy, metastasectomy plus systemic therapy versus systemic therapy alone // Trials. – 2009. – Vol. 23. – №10. – Р. 121.
29. Kodera Y., Ito S., Mochizuki Y. et al. A phase II study of radical surgery followed by postoperative chemotherapy with S-1 for gastric carcinoma with free cancer cells in the peritoneal cavity (CCOG0301 study) // Eur J Surg Oncol. – 2009. – Vol. 35. – №11. – P. 1158-1163.
30. Krook J.E., O'Connell M.J., Wieand H.S. et al. A prospective, randomized evaluation of intensivecourse 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer // Cancer. – 1991. – Vol. 67. – №10. – P. 2454-2458.
31. Ku G.Y., Ilson D.H. Esophagogastric cancer: targeted agents // Cancer Treat Rev. – 2010. – Vol. 36. – P. 235-248.
32. Kundel Y., Purim O., Idelevich E. et al. Postoperative chemoradiation for resected gastric cancer--is the Macdonald Regimen Tolerable? a retrospective multi-institutional study // Radiat Oncol. – 2011. – Vol. 29. – №6. – P. 127.
33. Lei Chen, Ming-Quan Song, Hui-Zhong Lin et al.. Chemotherapy and resection for gastric cancer with synchronous liver metastases // World J Gastroenterol. – 2013. – Vol. 19. – №13. – P. 2097-2103.
34. Leong T., Joon D.L., Willis D. et al. Adjuvant chemoradiation for gastric cancer using epirubicin, cisplatin, and 5-fluorouracil before and after threedimensional conformal radiotherapy with concurrent infusional 5-fluorouracil: a multicenter study of the Trans-Tasman Radiation Oncology Group // Int J Radiat Oncol Biol Phys. – 2011. – Vol. 79. – №3. – P. 690-695.
35. Lise M., Nitti D., Marchet A. et al. Final results of a phase III clinical trial of adjuvant chemotherapy with the modified fluorouracil, doxorubicin, and mitomycin regimen in resectable gastric cancer // J Clin Oncol. – 1995. – Vol. 13. – №11. – P. 2757-2763.
36. Macdonald J.S., Benedetti J., Smalley S. et al. Chemoradiation of resected gastric cancer: a 10-year follow-up of the phase III trial INT0116 (SWOG 9008) // J Clin Oncol. – 2009. – Vol. 27.
37. Macdonald J.S., Smalley S.R., Benedetti J. et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction // N Engl J Med. – 2001. – Vol. 345. – №10. – P. 725-730.
38. Maeda K., Chung Y.S., Ogawa Y. et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma // Cancer. – 1996. – Vol. 77.– P. 858-863.
39. Mari E., Floriani I., Tinazzi A. et al. Ann Oncol. Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomised trials // A study of the GISCAD (Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente) – 2000. – Vol. 11. – №7. – P. 837-843.
40. Mi D.H., Li Z., Yang K.H., et al. Surgery combined with intraoperative hyperthermic intraperitoneal chemotherapy (IHIC) for gastric cancer: a systematic review and meta-analysis of randomised controlled trials // Int J Hyperthermia. – 2013. – Vol. 29. – №2. – P. 156-167.
41. Minn A.Y., Hsu A., La T. et al. Comparison of intensity-modulated radiotherapy and 3-dimensional conformal radiotherapy as adjuvant therapy for gastric cancer // Cancer. – 2010. – Vol. 116. – №16. – P. 3943-3952.
42. Misleh J.G., Santoro P., Strasser J.F., Bennett J.J. Multidisciplinary management of gastric cancer // Surg Oncol Clin N Am. – 2013. – Vol. 22. – №2. – P. 247-264.
43. Nakajima T., Nashimoto A., Kitamura M., et al. Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group // Lancet. – 1999. – Vol. 354. – №9175. – P. 273-277.
44. Neri B., Cini G., Andreoli F. et al. Randomized trial of adjuvant chemotherapy versus control after curative resection for gastric cancer: 5-year follow-up // Br J Cancer. – 2001. – Vol. 84. – №7. – P. 878-880.
45. Ning Z., Chen D., Liu A. et al. Efficacy of Chemotherapy Combined with Targeted Arterial Infusion of Verapamil in Patients with Advanced Gastric Cancer // Cell Biochem Biophys. – 2013.
46. Ohtsu A., Shah M.A., Van Cutsem E. et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study // J Clin Oncol. – 2011. – Vol. 29.– P. 3968-3976.
47. Okuyama T., Korenaga D., Edagawa A. et al. Prognostic effects of oral anti-cancer drugs as adjuvant chemotherapy for 2 years after gastric cancer surgery // Surg Today. – 2012. – Vol. 42. – №8. – P. 734-740.
48. Orhan O., Eroglu C., Kaplan B. et al. Whole abdominal field versus standard field radiotherapy plus concomitant and adjuvant chemotherapy for patients with locally advanced gastric cancer // J Radiat Res. – 2011. – Vol. 52. – №2. – P. 168-175.
49. Osti M.F., Agolli L., Bracci S. Adjuvant chemoradiation with 5-fluorouracil or capecitabine in patients with gastric cancer after D2 nodal dissection // Anticancer Res. – 2012. – Vol. 32. – №4. – P. 1397-1402.
50. Panzini I., Gianni L., Fattori P.P. et al. Adjuvant chemotherapy in gastric cancer: a meta-analysis of randomized trials and a comparison with previous meta-analyses // Tumori. – 2002. – Vol. 88. – №1. – P. 21-27.
51. Paoletti X., Oba K., Burzykowski T., Michiels S. et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis // JAMA. – 2010. – Vol. 303. – №17. – P. 1729-1737.
52. Sakuramoto S., Sasako M., Yamaguchi T., Kinoshita T. et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine // N Engl J Med. – 2007. – Vol. 357. – №18. – P. 1810-1820.
53. Sasako M. Principles of surgical treatment for curable gastric cancer // J Clin Oncol. – 2003. – Vol. 21. – P. 274-275.
54. Sasako M., Kinoshita T., Furukawa H. Five-year results of the randomized phase III trial comparing S-1 monotherapy versus surgery alone for stage II/III gastric cancer patients after curative D2 gastrectomy ACTS-GC study // Ann Oncol. – 2010. – Vol. 21. – №8. – P. 225-249.
55. Sasako M., Sakuramoto S., Katai H. et al. Five-Year Outcomes of a Randomized Phase III Trial Comparing Adjuvant Chemotherapy With S-1 Versus Surgery Alone in Stage II or III Gastric Cancer // J Clin Oncol. – 2011. – Vol. 29. – P. 4387-4393.
56. Schwartz G.K., Winter K., Minsky B.D. et al. Randomized phase II trial evaluating two paclitaxel and cisplatin-containing chemoradiation regimens as adjuvant therapy in resected gastric cancer (RTOG-0114) // J Clin Oncol. – 2009. – Vol. 27. – №12. – P. 1956-1962.
57. Shah M.A., Jhawer M., Ilson D.H. et al. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma // J Clin Oncol. – 2011. – Vol. 29.– P. 868-874.
58. Shulman K., Haim N., Wollner M., Bernstein Z. et al. Postoperative chemotherapy in gastric cancer, consisting of etoposide, doxorubicin and cisplatin, followed by radiotherapy with concomitant cisplatin: A feasibility study // Oncol Lett. – 2012. – Vol. 3. – №5. – P. 1154-1158.
59. Sonnenblick A., Rottenberg Y., Kadouri L., Wygoda M. et al. Long-term outcome of continuous 5-fluorouracil/cisplatin-based chemotherapy followed by chemoradiation in patients with resected gastric cancer // Med Oncol. – 2012. – Vol. 29. – №5. – P. 3035-3038.
60. Sougioultzis S., Syrios J., Xynos I.D. et al. Palliative gastrectomy and other factors affecting overall survival in stage IV gastric adenocarcinoma patients receiving chemotherapy: a retrospective analysis // Eur J Surg Oncol. – 2011. – Vol. 37. – №4. – P. 312-318.
61. Sun P., Xiang J.B., Chen Z.Y. Meta-analysis of adjuvant chemotherapy after radical surgery for advanced gastric cancer // Br J Surg. – 2009. – Vol. 96. – №1. – P. 26-33.
62. Valentí V., Hernández-Lizoain J.L., Martínez Regueira F. et al. Analysis of postoperative morbidity in patients with gastric adenocarcinoma treated using a protocol of preoperative chemoradiotherapy and surgery // Cir Esp. – 2009. – Vol. 86. – №6. – P. 351-357.
63. Yamada S., Ritchim P., Charkrabandhu T., Jongraksat W. Combination 5-fluoruracil/cisplatinum versus 5-fluoruracil/leucovorin adjuvant chemotherapy efficacy for R0 gastric resection in locally invasive gastric cancer // J Med Assoc Thai. – 2012. – Vol. 95. – №12. – P. 1517-1523.
64. Ychou M., Boige V., Pignon J.P., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial // J Clin Oncol. – 2011. – Vol. 29. – №13. – P. 1715-1721.
65. Yonemura Y., Endou Y., Shinbo M. et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery // J Surg Oncol. – 2009. – Vol. 15. – №4. – P. 311-316.
66. Yoney A., Bati Y., Akboru H., Isikli L., Unsal M. A retrospective comparison of concurrent 5-fluorouracil or oral UFT in postoperative chemoradiation for gastric adenocarcinoma // Cancer Radiother. – 2010. – Vol. 14. – №1. – P. 19-23.
67. Yoshikawa T., Sasako M., Yamamoto S., Sano T., Imamura H., Fujitani K., Oshita H., Ito S., Kawashima Y., Fukushima N. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer // Br J Surg. – 2009. – Vol. 96. – №9. – P.1015-1022.
68. Yu C., Yu R., Zhu W., Song Y., Li T. Intensitymodulated radiotherapy combined with chemotherapy for the treatment of gastric cancer patients after standard D1/D2 surgery // J Cancer Res Clin Oncol. – 2012. – Vol. 138. – №2. – P. 255-259.
Рецензия
Для цитирования:
Арыбжанов Д.Т., Рахматуллина И.Р. АДЪЮВАНТНОЕ ЛЕЧЕНИЕ РАКА ЖЕЛУДКА. Креативная хирургия и онкология. 2013;(4):84-91. https://doi.org/10.24060/2076-3093-2013-0-4-84-91
For citation:
Arybzhanov D.T., Rakhmatullina I.R. ADJUVANT TREATMENT OF GASTRIC CANCER. Creative surgery and oncology. 2013;(4):84-91. (In Russ.) https://doi.org/10.24060/2076-3093-2013-0-4-84-91
Просмотров: 585
Послать статью по эл. почте 